RESUMEN
ABSTRACT: Induction chemotherapy (IC) and adjuvant chemotherapy (AC) are used to enhance tumor locoregional control and support early treatment for distant metastases. However, optimum combinatorial treatment of these chemoradiotherapy regimens with radiotherapy in curing locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Here, we evaluate the efficacy and therapeutic outcome of a combinatorial treatment strategy involving IC, intensity-modulated radiotherapy (IMRT), and AC, by retrospectively analyzing 243 NPC patients who were treated by IC followed by IMRT and AC. The rates of 3-/5-year local-regional control rate, distant failure-free rate (DFFR), progression-free survival (PFS), and overall survival (OS) were 93.3%/90.3%, 84.2%/79.4%, 79.6%/74.4%, and 84.0%/72.6%, respectively. The 3-/5-year OS rates of patients in stage III or IVA were 91.5%/75.1% and 86.5%/56.5%, respectively. Combination cisplatin with paclitaxel showed no significance in OS as compared to cisplatin plus 5-fluorouracil (P-valueâ=â.17). Total four-cycle IC and AC was significantly beneficious versus three-cycle in DFFR (P-valueâ=â.04), as well as total 6 chemotherapy cycles compared to 4 in DFFR and PFS (P-valueâ=â.03 and P-valueâ=â.01, respectively). All survival indicators were adversely affected by T-category, while N-category could only predict DFFR and PFS. Radiation dosage represented as a second prognostic factor for local control. We propose that IC combined with IMRT and AC for locoregionally advanced NPC shows effective treatment outcomes.
Asunto(s)
Quimioterapia Adyuvante/normas , Quimioterapia de Inducción/normas , Neoplasias Nasofaríngeas/terapia , Radioterapia de Intensidad Modulada/normas , Anciano , Quimioterapia Adyuvante/métodos , Quimioterapia Adyuvante/estadística & datos numéricos , China/epidemiología , Femenino , Humanos , Quimioterapia de Inducción/métodos , Quimioterapia de Inducción/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Neoplasias Nasofaríngeas/epidemiología , Neoplasias Nasofaríngeas/fisiopatología , Pronóstico , Radioterapia de Intensidad Modulada/métodos , Radioterapia de Intensidad Modulada/estadística & datos numéricos , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choice of a suitable topical treatment, the formulation matters and not just the active substances. This expert opinion paper was developed via a non-structured consensus process by Swiss dermatologists in hospitals and private practices to illustrate the current treatment options to general practitioners and dermatologists in Switzerland. Defining treatment goals together with the patient is crucial and increases treatment adherence. Patients' personal preferences and pre-existing experiences should be considered and their satisfaction with treatment and outcome regularly assessed. During the induction phase of "classical" mild-to-moderate psoriasis, the fixed combination of topical calcipotriol (Cal) 50 µg/g and betamethasone dipropionate (BD) 0.5 mg/g once daily is frequently used for 4-8 weeks. During the maintenance phase, a twice weekly (proactive) management has proved to reduce the risk of relapse. Of the fixed combinations, Cal/BD aerosol foam is the most effective formulation. However, the individual choice of formulation should be based on a patient's preference and the location of the psoriatic plaques. Tailored recommendations are given for the topical management of specific areas (scalp, facial, intertriginous/genital, or palmoplantar lesions), certain symptoms (hyperkeratotic or hyperinflammatory forms) as well as during pregnancy or a period of breastfeeding. As concomitant basic therapy, several emollients are recommended. If topical treatment alone does not appear to be sufficient, the regimen should be escalated according to the Swiss S1-guideline for the systemic treatment of psoriasis.
Asunto(s)
Corticoesteroides/administración & dosificación , Antiinflamatorios/administración & dosificación , Fármacos Dermatológicos/administración & dosificación , Guías de Práctica Clínica como Asunto , Psoriasis/tratamiento farmacológico , Administración Cutánea , Lactancia Materna , Combinación de Medicamentos , Cara , Femenino , Humanos , Quimioterapia de Inducción/normas , Quimioterapia de Mantención/normas , Masculino , Planificación de Atención al Paciente , Prioridad del Paciente , Embarazo , Cuero Cabelludo , SuizaRESUMEN
BACKGROUND: Variation in IS exists among pediatric liver transplant centers. While individual centers may publish their practice paradigms, current data on practices as a whole are lacking. This study sought to ascertain the IS protocols of pediatric liver transplant centers within the SPLIT to better understand variability and similarities among peer institutions. METHODS: A 27-item questionnaire was developed within the SPLIT Quality Improvement and Clinical Care Committee. The survey collected data regarding center demographics, IS practices, and treatment of acute cellular rejection. RESULTS: Twenty-eight (64%) SPLIT centers responded with 22 (79%) centers performing more than 10 transplants per year and 17 (61%) following more than 100 post-transplant recipients. All centers use a written protocol, and 25 (89%) have a dedicated transplant pharmacist/PharmD. Twenty-five (89%) centers use steroids for induction alone or in combination with thymoglobulin/interleukin-2 antibodies. All centers use tacrolimus for initial maintenance therapy. Most centers have specialized protocols for ABO-incompatible transplants, recipients with renal dysfunction, autoimmune liver diseases, and liver tumors. Treatment of rejection varied but was associated with escalation in IS. CONCLUSION: IS practices among pediatric liver transplant centers are similar including the use of written protocols, pharmacy involvement, steroids for induction, tacrolimus as initial IS, tacrolimus reduction/delay for renal dysfunction, and escalation of IS with rejection severity. However, other IS practices show wide variability including treatment for ABO-incompatible grafts and presumed rejection. This study serves as a foundation to guide prospective research linking IS practice to outcomes to determine best practice.
Asunto(s)
Rechazo de Injerto/prevención & control , Disparidades en Atención de Salud/estadística & datos numéricos , Terapia de Inmunosupresión/métodos , Inmunosupresores/uso terapéutico , Trasplante de Hígado , Pautas de la Práctica en Medicina/estadística & datos numéricos , Adolescente , Niño , Preescolar , Estudios Transversales , Quimioterapia Combinada , Rechazo de Injerto/terapia , Encuestas de Atención de la Salud , Humanos , Terapia de Inmunosupresión/normas , Terapia de Inmunosupresión/estadística & datos numéricos , Quimioterapia de Inducción/métodos , Quimioterapia de Inducción/normas , Quimioterapia de Inducción/estadística & datos numéricos , Lactante , Recién Nacido , Quimioterapia de Mantención/métodos , Quimioterapia de Mantención/normas , Quimioterapia de Mantención/estadística & datos numéricos , Pautas de la Práctica en Medicina/normas , Mejoramiento de la Calidad , Sociedades Médicas , Estados UnidosRESUMEN
The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment landscape in Crohn's disease (CD). The overall therapeutic achievements with TNF inhibitors such as infliximab, adalimumab, and certolizumab pegol paved the way to push the boundaries of treatment goals beyond symptomatic relief and toward cessation of objective signs of inflammation, including endoscopic remission. Even though these agents are widely used for the treatment of moderate to severe CD, heterogeneity still exists in translating evidence-based guidelines on the use of anti-TNF agents into actual treatment algorithms in CD. This might be due to several reasons including disparities in health expenditure policies; lack of harmonization between countries; and variations in assessment of disease severity, use of disease monitoring tools, or application of treatment targets by physicians. With the advent of biosimilars, patent-free versions of reference biologics are now available to minimize health inequalities in drug availability. In this context, this article aims to provide practical clinical guidance for the use of infliximab and adalimumab biosimilars in patients with moderate to severe CD by outlining different clinical scenarios that patients may encounter during their treatment journey.
Asunto(s)
Adalimumab/uso terapéutico , Biosimilares Farmacéuticos/uso terapéutico , Enfermedad de Crohn/tratamiento farmacológico , Quimioterapia de Inducción/normas , Infliximab/uso terapéutico , Inhibidores del Factor de Necrosis Tumoral/uso terapéutico , Humanos , Selección de Paciente , Guías de Práctica Clínica como Asunto , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
The overall objective of these guidelines is to provide evidence-based recommendations for the diagnosis and management of immunoglobulin G4 (IgG4)-related digestive disease in adults and children. IgG4-related digestive disease can be diagnosed only with a comprehensive work-up that includes histology, organ morphology at imaging, serology, search for other organ involvement, and response to glucocorticoid treatment. Indications for treatment are symptomatic patients with obstructive jaundice, abdominal pain, posterior pancreatic pain, and involvement of extra-pancreatic digestive organs, including IgG4-related cholangitis. Treatment with glucocorticoids should be weight-based and initiated at a dose of 0.6-0.8 mg/kg body weight/day orally (typical starting dose 30-40 mg/day prednisone equivalent) for 1 month to induce remission and then be tapered within two additional months. Response to initial treatment should be assessed at week 2-4 with clinical, biochemical and morphological markers. Maintenance treatment with glucocorticoids should be considered in multi-organ disease or history of relapse. If there is no change in disease activity and burden within 3 months, the diagnosis should be reconsidered. If the disease relapsed during the 3 months of treatment, immunosuppressive drugs should be added.
Asunto(s)
Enfermedades del Sistema Digestivo/tratamiento farmacológico , Enfermedad Relacionada con Inmunoglobulina G4/tratamiento farmacológico , Quimioterapia de Inducción/normas , Quimioterapia de Mantención/normas , Adulto , Peso Corporal , Niño , Enfermedades del Sistema Digestivo/diagnóstico , Enfermedades del Sistema Digestivo/inmunología , Relación Dosis-Respuesta a Droga , Cálculo de Dosificación de Drogas , Europa (Continente) , Medicina Basada en la Evidencia/métodos , Medicina Basada en la Evidencia/normas , Gastroenterología/métodos , Gastroenterología/normas , Glucocorticoides/administración & dosificación , Humanos , Enfermedad Relacionada con Inmunoglobulina G4/diagnóstico , Enfermedad Relacionada con Inmunoglobulina G4/inmunología , Inmunosupresores/administración & dosificación , Quimioterapia de Inducción/métodos , Quimioterapia de Mantención/métodos , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
BACKGROUND: A systemic review and meta-analysis of randomized controlled trials (RCTs) was performed to compare the efficacy, toxicity and safety of concurrent chemoradiotherapy (CCRT) with or without induction chemotherapy (IC) for locoregionally advanced nasopharyngeal carcinoma (NPC). METHODS: Research searching was performed in Web of Science, PubMed, The Cochrane Library, Embase, Chinese Biomedical Database, Chinese National Knowledge Infrastructure, Chongqing VIP Database for Chinese Technical Periodicals and Wanfang Database. RCTs including patients diagnosed with locoregionally advanced NPC without metastasis and randomly treated with IC plus CCRT and CCRT alone were included. Survival and outcome data were extracted and meta-analysis was performed using the Revman 5.3.0 software. RESULTS: Ten RCTs (2280 patients) were selected and used for pooled meta-analysis. In comparison with CCRT, IC plus CCRT treatment significantly improved the overall survival (OS; HRâ=â0.70, 95%CI 0.56-0.87, Pâ=â.002), progression-free survival (PFS; HRâ=â0.75, 95%CI 0.65-0.87, Pâ<â.0001), distant metastasis failure-free survival (DMFS; HRâ=â0.71, 95%CI 0.58-0.85, Pâ=â.0003) and loco-regional failure-free survival (LFES; HRâ=â0.72, 95%CI 0.59-0.88, Pâ=â.002) of patients with locoregionally advanced NPC. Patients treated with IC and CCRT had higher incidence of grade 3-4 leucopenia and thrombocytopenia than patients treated with CCRT alone (Pâ<â.0001). No significant difference in other grade 3-4 adverse events and radiation toxicity was observed between the two groups. IC combined with CCRT improved the survival of patients with locoregionally advanced NPC. CONCLUSIONS: Combined IC and CCRT therapy was an efficacy treatment regimen for locoregionally advanced NPC.
Asunto(s)
Quimioradioterapia/métodos , Quimioterapia de Inducción/normas , Neoplasias Nasofaríngeas/tratamiento farmacológico , Terapia Combinada , Humanos , Quimioterapia de Inducción/métodos , Quimioterapia de Inducción/tendencias , Neoplasias Nasofaríngeas/fisiopatología , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Resultado del TratamientoAsunto(s)
Antiinflamatorios/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Enfermedad de Crohn/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Fístula Rectal/tratamiento farmacológico , Corticoesteroides/uso terapéutico , Antibacterianos/uso terapéutico , Enfermedad de Crohn/complicaciones , Quimioterapia Combinada , Humanos , Quimioterapia de Inducción/métodos , Quimioterapia de Inducción/normas , Quimioterapia de Mantención/métodos , Quimioterapia de Mantención/normas , Fístula Rectal/etiología , Índice de Severidad de la EnfermedadRESUMEN
Locally advanced rectal cancer (LARC) carries higher risks of local and distant recurrence when treated with surgical resection alone. Multiple treatment strategies have been investigated to reduce recurrence risk and improve survival. Currently, there are 3 primary strategies for managing LARC: (1) preoperative long-course radiotherapy (RT) combined with radiosensitizing chemotherapy, which is better tolerated than postoperative chemoradiotherapy and provides tumor downstaging and improved pathologic complete response (pCR), followed by postoperative chemotherapy; (2) preoperative short-course RT alone as an alternative strategy for reducing the risk of local recurrence, followed by adjuvant postoperative chemotherapy; and (3) total neoadjuvant therapy with induction chemotherapy followed by chemoradiotherapy to improve pCR and reduce the difficulty of delivering chemotherapy in the postoperative setting. In addition to these currently recommended treatment paradigms, promising new strategies are available for treatment reduction. Neoadjuvant chemotherapy alone may allow for omission of RT in select patients with favorable LARC. For patients who have complete clinical responses to neoadjuvant chemotherapy and RT, nonoperative management is being considered for sphincter preservation, with surgery used as salvage. These are active areas of investigation in both institutional and cooperative group trials. The results are anticipated to provide better tailoring of neoadjuvant therapy based on patient tumor and disease response characteristics.
Asunto(s)
Recurrencia Local de Neoplasia/prevención & control , Guías de Práctica Clínica como Asunto , Neoplasias del Recto/terapia , Recto/patología , Canal Anal/cirugía , Protocolos de Quimioterapia Combinada Antineoplásica/normas , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Quimioradioterapia Adyuvante/métodos , Quimioradioterapia Adyuvante/normas , Quimioterapia Adyuvante/métodos , Quimioterapia Adyuvante/normas , Supervivencia sin Enfermedad , Humanos , Incidencia , Quimioterapia de Inducción/métodos , Quimioterapia de Inducción/normas , Oncología Médica/normas , Terapia Neoadyuvante/métodos , Terapia Neoadyuvante/normas , Recurrencia Local de Neoplasia/mortalidad , Recurrencia Local de Neoplasia/patología , Tratamientos Conservadores del Órgano/métodos , Tratamientos Conservadores del Órgano/normas , Proctectomía/efectos adversos , Proctectomía/métodos , Proctectomía/normas , Fármacos Sensibilizantes a Radiaciones/administración & dosificación , Neoplasias del Recto/epidemiología , Neoplasias del Recto/patología , Recto/cirugía , Terapia Recuperativa , Sociedades Médicas/normas , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe Crohn's disease (CD). AIM: We assessed comparative efficacy and safety of first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor [TNF]-α) agents) biologic therapy for moderate-severe CD, through a systematic review and network meta-analysis, and appraised quality of evidence (QoE) using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. METHODS: We identified randomised controlled trials (RCTs) in adults with moderate-severe CD treated with approved anti-TNF agents, anti-integrin agents and anti-IL12/23 agents, first-line or second-line, and compared with placebo or another active agent. Efficacy outcomes were induction and maintenance of clinical remission; safety outcomes were serious adverse events and infections. Network meta-analyses were performed, and ranking was assessed using surface under the cumulative ranking (SUCRA) probabilities. RESULTS: No head-to-head trials were identified. In biologic-naïve patients, infliximab (SUCRA,0.93) and adalimumab (SUCRA,0.75) were ranked highest for induction of clinical remission (moderate QoE). In patients with prior anti-TNF exposure, adalimumab (SUCRA, 0.91; low QoE, in patients with prior response or intolerance to anti-TNF agents) and ustekinumab (SUCRA, 0.71) were ranked highest for induction of clinical remission. In patients with response to induction therapy, adalimumab (SUCRA, 0.97) and infliximab (SUCRA, 0.68) were ranked highest for maintenance of remission. Ustekinumab had lowest risk of serious adverse events (SUCRA, 0.72) and infection (SUCRA, 0.71; along with infliximab, SUCRA, 0.83) in maintenance trials. CONCLUSION: Indirect comparisons suggest that infliximab or adalimumab may be preferred first-line agents, and ustekinumab a preferred second-line agent, for induction of remission in patients with moderate-severe CD. Head-to-head trials are warranted.
Asunto(s)
Factores Biológicos/uso terapéutico , Enfermedad de Crohn/tratamiento farmacológico , Adalimumab/uso terapéutico , Adulto , Anticuerpos Monoclonales/uso terapéutico , Enfermedad de Crohn/diagnóstico , Enfermedad de Crohn/epidemiología , Enfermedad de Crohn/patología , Exactitud de los Datos , Humanos , Quimioterapia de Inducción/métodos , Quimioterapia de Inducción/normas , Quimioterapia de Inducción/estadística & datos numéricos , Infliximab/uso terapéutico , Quimioterapia de Mantención/métodos , Quimioterapia de Mantención/normas , Metaanálisis en Red , Pronóstico , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/inmunología , Ustekinumab/uso terapéuticoRESUMEN
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper summarises the role of chemotherapy in head and neck cancer management, recent advances and what the future holds for this modality.
Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Antineoplásicos/administración & dosificación , Quimioradioterapia/normas , Humanos , Quimioterapia de Inducción/normas , Comunicación Interdisciplinaria , Terapia Molecular Dirigida/normas , Metástasis de la Neoplasia/tratamiento farmacológico , Recurrencia Local de Neoplasia/tratamiento farmacológico , Reino UnidoRESUMEN
BACKGROUND: The high levels of healthcare worker shortage is recognised as a severe impediment to increasing patients' access to antiretroviral therapy. This is particularly of concern where the burden of disease is greatest and the access to trained doctors is limited.This review aims to better inform HIV care programmes that are currently underway, and those planned, by assessing if task-shifting care from doctors to non-doctors provides both high quality and safe care for all patients requiring antiretroviral treatment. OBJECTIVES: To evaluate the quality of initiation and maintenance of HIV/AIDS care in models that task shift care from doctors to non-doctors. SEARCH METHODS: We conducted a comprehensive search to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and in progress) from 1 January 1996 to 28 March 2014, with major HIV/AIDS conferences searched 23 May 2014. We had also contacted relevant organizations and researchers. Key words included MeSH terms and free-text terms relevant to 'task shifting', 'skill mix', 'integration of tasks', 'service delivery' and 'health services accessibility'. SELECTION CRITERIA: We included controlled trials (randomised or non-randomised), controlled-before and after studies, and cohort studies (prospective or retrospective) comparing doctor-led antiretroviral therapy delivery to delivery that included another cadre of health worker other than a doctor, for initiating treatment, continuing treatment, or both, in HIV infected patients. DATA COLLECTION AND ANALYSIS: Two authors independently screened titles, abstracts and descriptor terms of the results of the electronic search and applied our eligibility criteria using a standardized eligibility form to full texts of potentially eligible or uncertain abstracts. Two reviewers independently extracted data on standardized data extraction forms. Where possible, data were pooled using random effects meta-analysis. We assessed evidence quality with GRADE methodology. MAIN RESULTS: Ten studies met our inclusion criteria, all of which were conducted in Africa. Of these four were randomised controlled trials while the remaining six were cohort studies.From the trial data, when nurses initiated and provided follow-up HIV therapy, there was high quality evidence of no difference in death at one year, unadjusted risk ratio was 0.96 (95% CI 0.82 to 1.12), one trial, cluster adjusted n = 2770. There was moderate quality evidence of lower rates of losses to follow-up at one year, relative risk of 0.73 (95% CI 0.55 to 0.97). From the cohort data, there was low quality evidence that there may be an increased risk of death in the task shifting group, relative risk 1.23 (95% CI 1.14 to 1.33, two cohorts, n = 39 160) and very low quality data reporting no difference in patients lost to follow-up between groups, relative risk 0.30 (95% CI 0.05 to 1.94).From the trial data, when doctors initiated therapy and nurses provided follow-up, there was moderate quality evidence that there is probably no difference in death compared with doctor-led care at one year, relative risk of 0.89 (95% CI 0.59 to 1.32), two trials, cluster adjusted n = 4332. There was moderate quality evidence that there is probably no difference in the numbers of patients lost to follow-up at one year, relative risk 1.27 (95% CI 0.92 to 1.77), P = 0.15. From the cohort data, there is very low quality data that death at one year may be lower in the task shifting group, relative risk 0.19 (95% CI 0.05 to 0.78), one cohort, n = 2772, and very low quality evidence that loss to follow-up was reduced, relative risk 0.34 (95% CI 0.18 to 0.66).From the trial data, for maintenance therapy delivered in the community there was moderate quality evidence that there is probably no difference in mortality when doctors deliver care in the hospital or specially trained field workers provide home-based maintenance care and antiretroviral therapy at one year, relative risk 1.0 (95% CI 0.62 to 1.62), 1 trial, cluster adjusted n = 559. There is moderate quality evidence from this trial that losses to follow-up are probably no different at one year, relative risk 0.52 (0.12 to 2.3), P = 0.39. The cohort studies did not report on one year follow-up for these outcomes.Across the studies that reported on virological and immunological outcomes, there was no clear evidence of difference whether a doctor or nurse or clinical officer delivered therapy. Three studies report on costs to patients, indicating a reduction in travel costs to treatment facilities where task shifting was occurring closer to patients homes. There is conflicting evidence regarding the relative cost to the health system, as implementation of the strategy may increase costs. The two studies reporting the patient and staff perceptions of the quality of care, report good acceptability of the service by patients, and general acceptance by doctors of the shifting of roles. One trial reported on the time to initiation of antiretroviral therapy, finding no clear evidence of a difference between groups. The same trial reports on new diagnosis of tuberculosis which favours nurse initiation of HIV care for increasing the numbers of diagnoses of tuberculosis made. AUTHORS' CONCLUSIONS: Our review found moderate quality evidence that shifting responsibility from doctors to adequately trained and supported nurses or community health workers for managing HIV patients probably does not decrease the quality of care and, in the case of nurse initiated care, may decrease the numbers of patients lost to follow-up.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Delegación Profesional/normas , Infecciones por VIH/tratamiento farmacológico , Pautas de la Práctica en Enfermería/normas , África , Estudios de Cohortes , Medicina General/normas , Infecciones por VIH/mortalidad , Accesibilidad a los Servicios de Salud/economía , Humanos , Quimioterapia de Inducción/normas , Perdida de Seguimiento , Quimioterapia de Mantención/normas , Pautas de la Práctica en Medicina/normas , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
BACKGROUND: Induction chemotherapy is a common therapeutic option for patients with locoregionally-advanced head and neck cancer (HNC), but it remains unclear which patients will benefit. In this study, we searched for biomarkers predicting the response of patients with locoregionally-advanced HNC to induction chemotherapy by evaluating the expression pattern of DNA repair proteins. METHODS: Expression of a panel of DNA-repair proteins in formalin-fixed paraffin embedded specimens from a cohort of 37 HNC patients undergoing platinum-based induction chemotherapy prior to definitive chemoradiation were analyzed using quantitative immunohistochemistry. RESULTS: We found that XPF (an ERCC1 binding partner) and phospho-MAPKAP Kinase 2 (pMK2) are novel biomarkers for HNSCC patients undergoing platinum-based induction chemotherapy. Low XPF expression in HNSCC patients is associated with better response to induction chemoradiotherapy, while high XPF expression correlates with a worse response (pâ=â0.02). Furthermore, low pMK2 expression was found to correlate significantly with overall survival after induction plus chemoradiation therapy (pâ=â0.01), suggesting that pMK2 may relate to chemoradiation therapy. CONCLUSIONS: We identified XPF and pMK2 as novel DNA-repair biomarkers for locoregionally-advanced HNC patients undergoing platinum-based induction chemotherapy prior to definitive chemoradiation. Our study provides insights for the use of DNA repair biomarkers in personalized diagnostics strategies. Further validation in a larger cohort is indicated.
Asunto(s)
Biomarcadores/metabolismo , Reparación del ADN/fisiología , Proteínas de Unión al ADN/metabolismo , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Quimioterapia de Inducción/normas , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas de Unión al ADN/genética , Perfilación de la Expresión Génica , Técnicas de Inactivación de Genes , Células HeLa , Neoplasias de Cabeza y Cuello/metabolismo , Humanos , Immunoblotting , Inmunohistoquímica , Quimioterapia de Inducción/métodos , Medicina de Precisión/métodos , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor. Here, we conducted a case-control study in these patients to compare the efficacy of CLAG-M induction (28 patients) versus standard 3+7 induction chemotherapy (24 patients). Response rates (P=0.014) and median overall survival (P=0.025) were 64% and 202 days (95% CI 37-367 days) versus 29% and 86 days (95% CI 36-136) in the CLAG-M and 3+7 cohorts, respectively. Median overall survival was 202 (95% CI 37-367 days) versus 86 days (95% CI 36-136) (P=0.025), respectively. CLAG-M has encouraging activity in this patient group.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica , Azacitidina/uso terapéutico , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Leucemia Mieloide Aguda/tratamiento farmacológico , Mitoxantrona/administración & dosificación , Síndromes Mielodisplásicos/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Quimioterapia Adyuvante/efectos adversos , Quimioterapia Adyuvante/normas , Cladribina , Citarabina , Progresión de la Enfermedad , Resistencia a Antineoplásicos/efectos de los fármacos , Femenino , Filgrastim , Factor Estimulante de Colonias de Granulocitos/efectos adversos , Humanos , Quimioterapia de Inducción/efectos adversos , Quimioterapia de Inducción/normas , Leucemia Mieloide Aguda/mortalidad , Leucemia Mieloide Aguda/patología , Masculino , Persona de Mediana Edad , Mitoxantrona/efectos adversos , Síndromes Mielodisplásicos/patología , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/efectos adversos , Insuficiencia del Tratamiento , Adulto JovenRESUMEN
Head and neck cancer represents 5 % of oncologic cases in adults. Early stage treatments are local with surgery and/or radiotherapy. For locally advanced stages, treatment requires radiotherapy combined with platinum-based drugs or cetuximab. Induction chemotherapy should be considered for selected cases. In the case of metastatic disease, adjuvant or palliative treatment is based on platinum agents and cetuximab.
Asunto(s)
Neoplasias de Cabeza y Cuello/terapia , Adulto , Algoritmos , Anticuerpos Monoclonales Humanizados/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Cetuximab , Esquema de Medicación , Neoplasias de Cabeza y Cuello/diagnóstico , Neoplasias de Cabeza y Cuello/patología , Humanos , Quimioterapia de Inducción/normas , Metástasis de la Neoplasia , Estadificación de Neoplasias/normasRESUMEN
High-dose chemotherapy and autologous stem-cell transplantation (HDT-ASCT) is standard therapy for younger patients with multiple myeloma (MM) who are physically fit enough to undergo the treatment. Nevertheless, MM remains incurable and strategies to prevent or delay relapse after HDT-ASCT are needed. A continuous therapy approach using maintenance therapy may provide sustained control of minimal residual disease after HDT-ASCT. Alternatively, extending treatment with novel induction regimens may delay the need for HDT-ASCT. Although there is some clinical evidence to support the use of these strategies, their efficacy has not been proven definitively in clinical trials; ongoing studies should help determine their merit in transplant-eligible patients with MM.